These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1709506)

  • 21. Neuronal sites mediating locomotor hyperactivity following central neurokinin agonist administration.
    Elliott PJ; Paris JM; Mitsushio H; Lorens SA
    Pharmacol Biochem Behav; 1990 Oct; 37(2):329-33. PubMed ID: 1706862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Behavioural effects of substance P through dopaminergic pathways in the brain.
    Iversen SD
    Ciba Found Symp; 1982; (91):307-24. PubMed ID: 6183078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reinforcing properties of the substance P C-fragment analog DiMe-C7 in Carassius auratus.
    Mattioli R; Coelho J; Martins A
    Braz J Med Biol Res; 1996 Apr; 29(4):495-9. PubMed ID: 8736114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of gamma-acetylenic GABA, an enzyme-activated irreversible inhibitor of GABA-transaminase, on dopamine pathways of the extrapyramidal and limbic systems.
    Palfreyman MG; Huot S; Lippert B; Schechter PJ
    Eur J Pharmacol; 1978 Aug; 50(4):325-36. PubMed ID: 699960
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of the mesolimbic dopamine system in cardiovascular homeostasis. Stimulation of the ventral tegmental area modulates the effect of vasopressin on blood pressure in conscious rats.
    van den Buuse M
    Clin Exp Pharmacol Physiol; 1998 Sep; 25(9):661-8. PubMed ID: 9750953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suggestive evidence for inhibitory effects of galanin on mesolimbic dopaminergic neurotransmission.
    Ericson E; Ahlenius S
    Brain Res; 1999 Mar; 822(1-2):200-9. PubMed ID: 10082897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stimulation of the ventral tegmental area enhances the effect of vasopressin on blood pressure in conscious rats.
    van Den Buuse M; Catanzariti R
    Br J Pharmacol; 2000 Jan; 129(1):29-36. PubMed ID: 10694199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Locomotor activation induced in rodent by substance P and analogues. Blockade of the effect of substance P by met-enkephalin antiserum.
    Naranjo JR; Del Rio J
    Neuropharmacology; 1984 Oct; 23(10):1167-71. PubMed ID: 6084200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of aversive stimulation on 5-hydroxytryptamine and dopamine metabolism in the rat brain.
    Ge J; Barnes NM; Costall B; Naylor RJ
    Pharmacol Biochem Behav; 1997 Nov; 58(3):775-83. PubMed ID: 9329072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sensitization to repeated enkephalin administration into the ventral tegmental area of the rat. II. Involvement of the mesolimbic dopamine system.
    Kalivas PW
    J Pharmacol Exp Ther; 1985 Nov; 235(2):544-50. PubMed ID: 4057084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Substance P modulation of the mesolimbic dopamine system.
    Kalivas P
    Prog Clin Biol Res; 1985; 192():403-8. PubMed ID: 2417255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain.
    Costall B; Domeney AM; Naylor RJ; Tyers MB
    Br J Pharmacol; 1987 Dec; 92(4):881-94. PubMed ID: 2962686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intracerebroventricular administration of substance P increases dopamine content in the brain of 6-hydroxydopamine-lesioned rats.
    Krasnova IN; Bychkov ER; Lioudyno VI; Zubareva OE; Dambinova SA
    Neuroscience; 2000; 95(1):113-7. PubMed ID: 10619467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dopamine agonist action in mesolimbic, cortical and extrapyramidal areas to modify spontaneous climbing behaviour of the mouse.
    Costall B; Eniojukan JF; Naylor RJ
    Psychopharmacology (Berl); 1985; 86(4):452-7. PubMed ID: 3929317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reinforcing effects of neurokinin substance P in the ventral pallidum: mediation by the tachykinin NK1 receptor.
    Nikolaus S; Huston JP; Hasenöhrl RU
    Eur J Pharmacol; 1999 Apr; 370(2):93-9. PubMed ID: 10323256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pressor responses to electrical and chemical stimulation of the rat brain A10 dopaminergic system.
    Cornish JL; van den Buuse M
    Neurosci Lett; 1994 Aug; 176(2):142-6. PubMed ID: 7530350
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular effects of spinal cord substance P: studies with a stable receptor agonist.
    Keeler JR; Charlton CG; Helke CJ
    J Pharmacol Exp Ther; 1985 Jun; 233(3):755-60. PubMed ID: 2409270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pretreatment with fragments of substance-P or with cholecystokinin differentially affects recovery from sub-total nigrostriatal 6-hydroxydopamine lesion.
    Nikolaus S; Huston JP; Schwarting RK
    Neural Plast; 1999; 6(4):77-89. PubMed ID: 10714262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Behavioural activation induced in the rat by substance P infusion into ventral tegmental area: implication of dopaminergic A10 neurones.
    Kelley AE; Stinus L; Iversen SD
    Neurosci Lett; 1979 Mar; 11(3):335-9. PubMed ID: 514544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuromedin N mimics the actions of neurotensin in the ventral tegmental area but not in the nucleus accumbens.
    Kalivas PW; Richardson-Carlson R; Duffy P
    J Pharmacol Exp Ther; 1986 Sep; 238(3):1126-31. PubMed ID: 3755755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.